Edward B. Mougey CURRICULUM VITAE (2015_C).pdfCURRICULUM VITAE CONTACT INFORMATION Name: Edward B. Mougey Address: 1910 Hibernia Ct. Jacksonville, FL 32223 Telephone: (904) 292-1826

Edward B. Mougey

1 Thursday, May 23, 2013

CURRICULUM VITAE

CONTACT INFORMATION

Name: Edward B. Mougey Address: 1910 Hibernia Ct. Jacksonville, FL 32223 Telephone: (904) 292-1826 Cell Phone: (904) 803-9011 Personal Email: [email protected]

PERSONAL INFORMATION

Current Business Address: Nemours Biomedical Research

Nemours Children’s Clinic 807 Children’s Way Jacksonville, FL 32207 Business Phone: (904) 697-3781 Business Fax: (904) 697-3425 Business Email 1: [email protected] Business Email 2: [email protected] Date of Birth: October 31, 1960 Place of Birth: Washington, DC Marital Status: Married Social Security Number: Available on request

EDUCATION

Postdoctoral Fellow: Johns Hopkins University School of Medicine,

Department of Biological Chemistry, Baltimore, MD, 1988-1996.

Adviser: Barbara Sollner-Webb Research Interests: Transcriptional Activation of

the Xenopus laevis ribosomal RNA genes. Ribosomal RNA processing in Xenopus laevis.

mailto:[email protected]

mailto:[email protected]

Edward B. Mougey


Graduate (Ph.D.): University of Delaware, Department of Chemistry, Newark, DE, 1982-1988.

Adviser: Don Dennis Doctoral thesis: The catalytic mechanism of RNA

polymerase II from S. cerevisiae. Undergraduate (B.S.): University of Maryland, College Park, MD, 1978-

1982. Major: Chemistry Minor: Biochemistry

PROFESSIONAL HISTORY

Research Scientist Nemours Children’s Clinic, Cellular and Molecular

Medicine Laboratory, Jacksonville, FL, 1999 – Present.

Research Associate II Nemours Children’s Clinic, Cellular and Molecular

Medicine Laboratory, Jacksonville, FL, 1997 – 1998. Staff Fellow Johns Hopkins University School of Medicine,

Department of Biological Chemistry, Baltimore, MD, 1988 – 1996.

Teaching Assistant University of Delaware, Department of Chemistry,

Newark, DE. Bioorganic Chemistry Laboratory, four semesters; 1986 – 1987.

Competitive Departmental Fellowship University of Delaware, Department of Chemistry,

Newark, DE, 1985. Teaching Assistant University of Delaware, Department of Chemistry,

Newark, DE,. Organic Chemistry Laboratory, six semesters; 1982 – 1984.

Additional Training Max-Plank Institute für Biochemie, Munich,

Germany, 1983. Project: Large scale purification of E. Coli RNA Polymerase.

Edward B. Mougey


PROFESSIONAL AFFILIATIONS

American Thoracic Society

CURRENT RESEARCH

Pharmacogenetics of Proton Pump Inhibitors (PPIs). PPIs suppress acid production in the stomach and are used to treat symptoms associated with gastro-esophageal reflux disease (GERD), a condition that affects over 60 million individuals in the United States. The most frequently prescribed PPIs are metabolized primarily by CYP2C19. Inactive gene variants of CYP2C19 are prevalent in the population with ~18% of whites and blacks, and ~50% of Asians having at least one inactive copy resulting in decreased CYP2C19 activity. In addition, a common CYP2C19 gene variant has been identified that results in increased CYP2C19 activity. Together, these prevalent CYP2C19 variants can result in greater risk of experiencing toxic side effects (supratherapeutic exposure) or greater risk of treatment failure (subtherapeutic exposure) and unnecessary progression to surgical solutions. Recently, PPI utilization has been associated with an increased incidence of potentially life-threatening comorbidities including ear, sinus, throat, bronchiole, and lung infections with pneumonia being the most serious. In a cohort of asthmatics who received PPI therapy to determine if treatment of undiagnosed GRED could relieve symptoms associated with asthma, we found an increase in upper respiratory tract infections and worsening asthma symptoms among individuals who carried an inactive CYP2C19 gene variant suggesting that the risk of experiencing comorbidities while on PPI therapy may be associated with CYP2C19 diplotype. Currently, we are expanding our analysis to include larger cohorts of obese, asthmatic, or IBD patients to confirm our initial observations in these patient populations and provide evidence for the importance of genotype-guided PPI prescribing.

CURRENT GRANT SUPPORT

Organization: Merck Investigator Initiated Studies Program for

Singulair Principal Investigator: E. Mougey, Ph.D. Dates: 03/10 – 8/15 Title: Genotype Stratified Pharmacokinetic Study of

Montelukast Goal: Assess the pharmacokinetics of montelukast in

individuals who are homozygous for SLCO2B1{NM_007256.2}:c.[935G>A].

Organization: National Institutes of Health Principal Investigator: J. Lang, MD

Edward B. Mougey


Role: Research Scientist Dates: 05/10 – 4/16 Title: Obesity and asthma: Genetics and nutrigenetic

response to omega-3 fatty acids Goal: The goal of this study is to develop expertise in

Patient-oriented clinical and translational science; and to better understand the complex interaction between obesity and asthma.

Organization: Nemours Biomedical Research Principal Investigator: K. Blake, PHARMD Role: Research Scientist Dates: 07/11 – 06/13 Title: Metabolomics and Molecular Genetics of Asthma

in Sickle Cell Disease (MeG-ASC) Goal: The goal of this project is to use metabolomics to

characterize the molecular phenotype of asthma in sickle cell disease.

Organization: Nemours Biomedical Research Principal Investigator: E. Mougey, Ph.D. Dates: 07/11 – 06/13 Title: Influence of SLCO2B1 Variants on the Kinetics of

Montelukast Transport Goal: The goal of this project is to characterize the

kinetics of montelukast transport by variants of SLCO2B1 expressed in xenopus oocytes.

Organization: Nemours Biomedical Research Principal Investigator: J. Lima, PHARMD Role: Research Scientist Dates: 07/11 – 06/13 Title: Associations between vit D levels and vit D gene

variants in Peruvian adolescents with asthma. Goal: The goal of this project is to determine associations

between variants in vitamin D candidate genes and asthma symptoms in Peruvian children with asthma.

Organization: Nemours Biomedical Research Principal Investigator: J. Lima, PHARMD Role: Research Scientist

Edward B. Mougey


Dates: 07/11 – 06/13 Title: Pharmacometabolomics of Asthma Controller

Drugs Goal: The goal of this project is to determine associations

between metabolomic profiles in EBC and response to different asthma controller drugs.

Organization: Nemours Biomedical Research Principal Investigator: E. Mougey, Ph.D. Dates: 07/11 – 06/13 Title: Role of Regulatory T-cell Function in Asthma

Severity of Obese Children. Goal: The goal of this project is to determine if poorly

controlled asthma in the obese is associated with a reduction in mTreg number and activity.

PENDING GRANT SUPPORT

Granting Organization: Doris Duke Charitable Foundation Principal Investigator: K. Blake, PHARMD Role: Research Scientist Dates: 9/13 - 8/16 Title: Trial of Montelukast to Reduce Asthma and

Respiratory-Related Pain Symptoms in Children with Asthma and Sickle Cell Disease

Granting Organization: National Institutes of Health, New York College of

Medicine Principal Investigator: A. Dozor, MD Role: Research Scientist Dates: 9/12 - 8/15 Title: P-SATIN: Clinical Coordinating Center Application Granting Organization: National Institutes of Health Principal Investigator: J. Lima, PHARMD Role: Research Scientist Dates: 9/12 - 8/15 Title: Application of Systems Biology Study of Long-acting

Beta agonists in Asthma (LASST) Granting Organization: Thrasher Research Foundation Principal Investigator: J. Lima, PHARMD

Edward B. Mougey


Role: Research Scientist Dates: 06/13 – 05/16 Title: Pharmacogenetic Study of Lansoprazole in Children

with GERD

PAST GRANT SUPPORT

Granting Organization: Thrasher Research Fund Principal Investigator: J. Lima, PHARMD Role: Research Scientist Dates: 2/1/2010-1/31/2013 Title: Effect of Gly16Arg polymorphism in ADRB2 gene on

asthma control in children receiving long acting beta agonists

Goal: Determine the effect of Gly16Arg polymorphism on the response to LABA in children.

Granting Organization: James and Esther King Biomedical Research

Program Principal Investigator: J. Lang, M.D. Role: Research Scientist Dates: 07/01/2009-06/30/2012 Title: Environmental Genetics (En-Gen): Effect of

Environmental Tobacco Smoke and Genetic Variation on Leukotriene Production in Asthmatic Children

Goal: Determine associations among ETS exposure, leukotriene production, and asthma severity.

Granting Organization: Nemours Biomedical Research Principal Investigator: E. Mougey, Ph.D. Dates: 07/01/2009 – 3/30/2011 Title: Aptamer Based Sensor of Chronic Leukotriene

Exposure Goal: Develop a nucleic acid based sensor for chronic

leukocyte leukotriene exposure. Granting Organization: Nemours Biomedical Research Principal Investigator: Rob Olney, MD Role: Research Scientist Dates: 07/01/2009 – 6/30/2010

Edward B. Mougey


Title: In Vitro Models of Endochondral Growth – Effects of Inflammation and C-Type Natriuretic Peptide on Insulin-Like Growth Factor-I Signaling

Goal: Describe the steady state IGF-I signaling events in an IN VITRO in model of endochondral growth.

Granting Organization: Merck Investigator Initiated Studies Program for

Singulair Principal Investigator: E. Mougey, Ph.D. Dates: 08/01/2007 – 8/01/2009 Title: Characterization of Transporter Mediated Uptake

of Montelukast in Humans Goal: Determine if intestinal transport proteins mediate

absorption of montelukast in humans. Granting Organization: Pharmacia Endocrine Care International Fund for

Research Principal Investigator: E. Mougey, Ph.D. Dates: 01/01/2003 – 12/31/2005 Title: Determining the Gene Expression Profile of

Growth-Plate Chondrocytes from Subjects with Skeletal Dysplasias.

Goal: Identify disrupted signaling pathways in patients with skeletal dysplasias.

Granting Organization: Nemours Biomedical Research Principal Investigator: E. Mougey, Ph.D. Dates: 01/01/2003 – 12/31/2005 Title: Determining the Gene Expression Profile of

Growth-Plate Chondrocytes from Subjects with Skeletal Dysplasias. (Match account).

Goal: Identify disrupted signaling pathways in patients with skeletal dysplasias.

Granting Organization: Nemours Biomedical Research Principal Investigator: R.Olney, M.D. Role: Research Scientist Dates: 11/06/2000 – 09/31/2005 Title: Determining the complete gene expression profile

in human growth-plate chondrocytes. Goal: Microarray analysis of growth-plate gene

expression.

Edward B. Mougey


Granting Organization: National Institutes of Health, RO1 AR45298-01A2 Principal Investigator: R.Olney, M.D. Role: Research Scientist Dates: 09/28/1999 – 08/31/2004 Title: Regulatory Mechanisms of Growth-Plate

Chondrocytes. Goal: To determine the regulatory molecules involved in

chondrocyte differentiation and to develop a model cell culture system for study.

Granting Organization: Nemours Biomedical Research Principal Investigator: E. Mougey, Ph.D. Dates: 7/1/00 – 6/30/01 Title: Towards a Molecular Diagnostic Tool for

Intrauterine Growth Retardation: Are Mutations in Mitochondrial Ribosomal Protein Genes Causative for Russell-Silver Syndrome.

Goal: Determine if mutations in MRPL12 lead to Russell-Silver Syndrome.

Granting Organization: Nemours Biomedical Research Principal Investigator: J. Sylvester, Ph.D. Role: Research Associate II Dates: 10/01/1998 – 12/31/2000 Title: Characterization of the genes for human

mitochondrial ribosomal proteins. Goal: Use in silico methods to identify the human

mitochondrial ribosomal protein genes.

PUBLICATIONS

1. Mougey,E.B. and Dennis,D. (1988). Formation and characterization of precise eucaryotic

transcription complexes using a semisynthetic DNA template and specific oligoribonucleotide primers. Anal. Biochem 171, 256-265.

2. Pape,L.K., Windle,J.J., Mougey,E.B., and Sollner-Webb,B. (1989). The Xenopus ribosomal DNA 60-

and 81-base-pair repeats are position-dependent enhancers that function at the establishment of the preinitiation complex: analysis in vivo and in an enhancer-responsive in vitro system. Mol Cell Biol 9, 5093-5104. PMCID: PMC363661.

Edward B. Mougey


3. Sollner-Webb,B., Pape,L., Ryan,K., Mougey,E.B., Poretta,R., Nikolov,E., Paalman,M.H., Lazdins,I., and Martin,C. (1991). Expression of mouse and frog rRNA genes: transcription and processing. Mol Cell Biochem 104, 149-154.

4. Sollner-Webb,B. and Mougey,E.B. (1991). News from the nucleolus: rRNA gene expression. Trends

Biochem Sci 16, 58-62. 5. Mougey,E.B., O'Reilly,M., Osheim,Y., Miller,O.L., Jr., Beyer,A., and Sollner-Webb,B. (1993). The

terminal balls characteristic of eukaryotic rRNA transcription units in chromatin spreads are rRNA processing complexes. Genes Dev 7, 1609-1619.

6. Mougey,E.B., Pape,L.K., and Sollner-Webb,B. (1993). A U3 small nuclear ribonucleoprotein-

requiring processing event in the 5' external transcribed spacer of Xenopus precursor rRNA. Mol Cell Biol 13, 5990-5998. PMCID: PMC364653.

7. Sheng,N., Mougey,E.B., Kelly,S., and Dennis,D. (1993). Wheat germ and yeast RNA polymerase II:

photoaffinity labeling by 4-thiouracil 5'-monophosphate positioned uniquely at the 3' end of an enzyme-bound [32P]-containing transcript. Biochemistry 32, 2248-2253.

8. Mougey,E.B., Pape,L.K., and Sollner-Webb,B. (1996). Virtually the entire Xenopus laevis rDNA

multikilobase intergenic spacer serves to stimulate polymerase I transcription. J Biol Chem. 271, 27138-27145.

9. Osheim,Y.N., Mougey,E.B., Windle,J., Anderson,M., O'Reilly,M., Miller,O.L., Jr., Beyer,A., and

Sollner-Webb,B. (1996). Metazoan rDNA enhancer acts by making more genes transcriptionally active. J Cell Biol 133, 943-954.

10. O'Brien,T.W., Fiesler,S.E., Denslow,N.D., Thiede,B., Wittmann-Liebold,B., Mougey,E.B.,

Sylvester,J.E., and Graack,H.R. (1999). Mammalian mitochondrial ribosomal proteins (2). Amino acid sequencing, characterization, and identification of corresponding gene sequences. J Biol Chem. 274, 36043-36051.

11. Olney,R.C. and Mougey,E.B. (1999). Expression of the components of the insulin-like growth factor

axis across the growth-plate. Mol Cell Endocrinol 156, 63-71. 12. O'Brien,T.W., Liu,J., Sylvester,J.E., Mougey,E.B., Fischel-Ghodsian,N., Thiede,B., Wittmann-

Liebold,B., and Graack,H.R. (2000). Mammalian mitochondrial ribosomal proteins (4). Amino acid sequencing, characterization, and identification of corresponding gene sequences. J Biol Chem. 275, 18153-18159.

13. Spirina,O., Bykhovskaya,Y., Kajava,A.V., O'Brien,T.W., Nierlich,D.P., Mougey,E.B., Sylvester,J.E.,

Graack,H.R., Wittmann-Liebold,B., and Fischel-Ghodsian,N. (2000). Heart-specific splice-variant of a

Edward B. Mougey


human mitochondrial ribosomal protein (mRNA processing; tissue specific splicing). Gene 261, 229-234.

14. Wang,J., Mougey,E.B., David,C.J., Humma,L.M., Johnson,J.A., Lima,J.J., and Sylvester,J.E. (2001).

Determination of human beta(2)-adrenoceptor haplotypes by denaturation selective amplification and subtractive genotyping. Am J Pharmacogenomics 1, 315-322.

15. Olney,R.C., Mougey,E.B., Wang,J., Shulman,D.I., and Sylvester,J.E. (2002). Using real-time,

quantitative PCR for rapid genotyping of the steroid 21-hydroxylase gene in a north Florida population. J Clin Endocrinol Metab 87, 735-741.

16. Olney,R.C., Wang,J., Sylvester,J.E., and Mougey,E.B. (2004). Growth factor regulation of human

growth plate chondrocyte proliferation in vitro. Biochem Biophys Res Commun 317, 1171-1182. 17. Sylvester,J.E., Fischel-Ghodsian,N., Mougey,E.B., and O'Brien,T.W. (2004). Mitochondrial ribosomal

proteins: candidate genes for mitochondrial disease. Genet Med 6, 73-80. 18. Balagopal,P., Olney,R.C., Darmaun, D., Mougey,E., Dokler,M., Sieck,G., Hammond,D. (2006).

Oxandrolone enhances skeletal muscle myosin synthesis and alters global gene expression profile in Duchenne muscular dystrophy. Am J Physiol Endocrinol Metab. 290(3):E530-9.

19. Mougey,E.B., Feng,H., Castro,M., Irvin,C.G., Lima,J.J. (2009). Absorption of Montelukast is

Transporter Mediated: a Common Variant of OATP2B1 is Associated with Reduced Plasma Concentrations and Poor Response. Pharmacogenet Genomics. 19(2):129-38.

20. Mougey, E.B., Lang, J.E., Wen, X., Lima, J.J. (2010). Effect of Citrus Juice and SLCO2B1 Genotype on

the Pharmacokinetics of Montelukast. J Clin Pharmacol. 2011 May;51(5):751-60; doi:10.1177/0091270010374472

21. Mougey, E.B., Chen, C., Tantisira, K.G., Blake, K.V., Peters, S.P., Wise, R.A., Weiss, S.T., Lima, J.J.

Pharmacogenetics of asthma controller treatment. Pharmacogenomics J. 2012 Feb 28. doi: 10.1038/tpj.2012.

22. Lang, J.E., Mougey, E.B., Allayee,. H, et al. Nutrigenetic response to omega-3 fatty acids in obese

asthmatics (NOOA): Rationale and methods. Contemporary clinical trials 2013;34:326-35.

23. Lang, J.E., Dozor, A.J., Holbrook, J.T., Mougey, E., Krishnan, S., Sweeten, S., Wise, R.A., Teague, W.G., Wei, C.Y., Shade, D., Lima, J.J. Biologic mechanisms of environmental tobacco smoke in children with poorly controlled asthma: results from a multicenter clinical trial.; American Lung Association-Asthma Clinical Research Centers. J Allergy Clin Immunol Pract. 2013 Mar;1(2):172-80. doi: 10.1016/j.jaip.2012.11.006.

Edward B. Mougey


24. Lima, J.J., Lang, J.E., Mougey, E.B., Blake, K.B., Gong, Y., Holbrook, J.T., Wise, R.A., Teague, W.G. Association of CYP2C19 Polymorphisms and Lansoprazole-Associated Respiratory Adverse Effects in Children. J Pediatr. 2013 Apr 24. doi:pii: S0022-3476(13)00293-X. 10.1016/j.jpeds.2013.03.017.

25. Mougey, E., Lang, J.E., Allayee, H., Teague, W.G., Dozor, A.J., Wise, R.A., Lima, J.J. ALOX5

Polymorphism associates with increased leukotriene production and reduced lung function and asthma control in children with poorly controlled asthma. Clin Exp Allergy. 2013 May;43(5):512-20. doi: 10.1111/cea.12076.

26. Checkley, W., Robinson, C.L., Baumann, L.M., Hansel, N.N., Romero, K.M., Pollard, S.L., Wise, R.A.,

Gilman, R.H., Mougey, E., Lima, J.J. ; PURA Study Investigators. 25-hydroxy vitamin D levels are associated with childhood asthma in a population-based study in Peru. Clin Exp Allergy. 2015 Jan;45(1):273-82. doi: 10.1111/cea.12311.

27. Baumann, L.M., Romero, K.M., Robinson, C.L., Hansel, N.N., Gilman, R.H., Hamilton, R.G., Lima, J.J., Wise, R.A., Checkley, W. ; PURA Study Investigators. Prevalence and risk factors for allergic rhinitis in two resource-limited settings in Peru with disparate degrees of urbanization. Clin Exp Allergy. 2015 Jan;45(1):192-9. doi: 10.1111/cea.12379.

28. Tomaino, K., Romero, K.M., Robinson, C.L., Baumann, L.M., Hansel, N.N., Pollard, S.L., Gilman, R.H.,

Mougey, E., Lima, J.J., Checkley, W.; PURA study investigators. Association Between Serum 25-Hydroxy Vitamin D Levels and Blood Pressure Among Adolescents in Two Resource-Limited Settings in Peru. Am J Hypertens. 2015 Jan 19. pii: hpu264. PMID: 25600222.

29. Lang JE, Holbrook JT, Mougey EB, et al. Lansoprazole Is Associated with Worsening Asthma Control

in Children with the CYP2C19 Poor Metabolizer Phenotype. Ann Am Thorac Soc. 2015 Jun;12(6):878-85. doi: 10.1513/AnnalsATS.201408-391OC. PMID: 25844821.

30. Smith LJ, Kalhan R, Wise RA, et al. Effect of a soy isoflavone supplement on lung function and

clinical outcomes in patients with poorly controlled asthma: a randomized clinical trial. JAMA. 2015 May 26;313(20):2033-43. doi: 10.1001/jama.2015.5024. PMID: 26010632.

PUBLICATIONS IN PREPARATION

1. Mougey, E.B., Blake, K.V., Lang, J.E., et al. Association of Genetic Variants in NPPA and NPR1 with the Prevalence of Asthma. Clinical and Experimental Allergy.

Edward B. Mougey


2. Mougey, E.B., Lang, J.E., Lima, J.J., Blake, K.V., Robinson, C., Baumann, L., Hansel, N., Romero, K., Pollard, S., Wise, R., Gilman, R., Checkley, W. Association of Vitamin D Pathway Candidate Gene Variants with Serum Vitamin D Levels in Rural vs. Urban Peruvian Populations. Clinical and Experimental Allergy.

PRESENTATIONS

1. Mougey,E.B., Dennis,D. Yeast RNA Pol II: Construction and Characterization of a Semi-Synthetic

Template Which Allows Precision Initiation in the Absence of Added Initiation Factors. Federation of American Societies for Experimental Biology, American Society of Biological Chemists, Philadelphia, PA, June 7-11, 1987.

2. Sollner-Webb,B., Pape,L., Henderson,S., Ryan,K., Poretta,R., Mougey,E.B., Paalman,M., Tower,J.

rDNA Transcription in Mouse and Frog. Ribosome Synthesis, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, September 21-25, 1988.

3. Mougey,E.B., Pape,L., Sollner-Webb,B. Conserved ETS Processing in Xenopus rRNA. Molecular

Mechanisms of Cellular Growth. Geisinger Clinic, Sigfried and Janet Weis Center for Research, Danville, Pennsylvania, June 17-21, 1990.

4. Mougey,E.B., Pape,L., Sollner-Webb,B. Conserved ETS Processing in Xenopus rRNA. RNA

processing, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, May 15-19, 1991. 5. O'Reilly,M., Mougey,E.B., Sollner-Webb,B., Miller,O.L.Jr. Terminal Knob Formation and Processing

of Xenopus rRNA. RNA processing, Keystone, Colorado, May 27-31, 1992. 6. Mougey,E.B., O'Reilly,M., Sollner-Webb,B. Processing in the 5' ETS of Xenopus Pre-rRNA: U3

Requirement and its Visualization. RNA processing, Keystone, Colorado, May 27-31, 1992. 7. Mougey,E.B., O'Reilly,M., Osheim,Y., Miller,O.L.Jr., Beyer,A., Sollner-Webb,B. The Terminal Balls

Characteristic of Eukaryotic rRNA Transcription Units in Chromatin Spreads are rRNA Processing Complexes. RNA Processing, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, May 19-23, 1993.

8. Li,W.M., Gonzalez,I.L., Mougey,E.B., Sylvester,J.E.. A p53-dependent enhancer element and a

spacer promoter in the human ribosomal RNA gene. The Ribosome, The Netherlands, 1997. 9. Olney,R.C., Mougey,E.B. IGF-I expression is down-regulated in hypertrophic growth-plate

chondrocytes in vivo but not in vitro. Presented before the Third International Conference of the Growth Hormone Research Society, San Francisco, September, 1998.

Edward B. Mougey


10. Olney,R.C., Mougey,E.B., Cummings,R.J., Hahn,G.A.Jr., Loveless,E.A., Mazur,J.M. Multiple IGF-I mRNA Transcripts are Differentially Expressed in Adolescent Human and Fetal Bovine Growth-Plate Chondrocytes. The 21st Annual Meeting of the American Society for Bone and Mineral Research, St. Louis, September, 1999.

11. Mougey,E.B., Maguire,B.A., Liu,J., Sylvester,J.E., and O’Brien,T.W. Human Mitochondrial Ribosomal

Protein Gene L12: A Candidate Gene for Russell-Silver Syndrome. The American Society for Human Genetics, San Francisco, October, 1999.

12. Mougey,E.B., Maguire,B.A., Liu,J., Sylvester,J.E., O’Brien,T.W. Human Mitochondrial Ribosomal

Protein Gene L12: A Candidate Gene for Russell-Silver Syndrome. The Keystone Symposium on Mitochondrial Dysfunction and Pathogenesis, Santa Fe, January, 2000.

13. Mougey,E.B., Wang,J., Olney,R. Potential new mutations in the 21-hydroxylase gene causing

congenital adrenal hyperplasia. The American Society for Human Genetics, Philadelphia, October, 2000.

14. Mougey,E.B., Mann,K.J., Sylvester,J.E., Olney,R. Expression profiling of osteochondrodysplasia

causative genes across the human growth plate. American Society of Human Genetics, Salt Lake City, UT, October 25-29, 2005.

15. Mougey,E.B., Mann,K.J., Maguire,B.A., Olney,R, Sylvester,J.E. Expression profiling of extracellular

matrix genes across the human growth plate. American Society of Cell Biologists, San Diego, CA, December 9-13, 2006.

16. Mougey,E.B., Feng,H., Castro,M., Irvin,C., Lima,J J. Montelukast Plasma Concentration Associates

With A Common SNP in SLCO2B1. American Society for Clinical Pharmacology and Therapeutics, Orlando, FL, April 2-5, 2008.

17. Mougey,E.B., Egelund,E., Feng,H., Castro,M., Irvin,C., Lima,J J. Transporter Mediated Absorption of

Montelukast in a Caco-2 Model System. American Society for Clinical Pharmacology and Therapeutics, Orlando, FL, April 2-5, 2008.

18. Mougey, E.B., Chen, C., Tantisira, K.G., Blake, K.V., Peters, S., Robert A. Wise, R.A., Weiss, S.T., Lima,

J.J. Response To Fluticasone And Montelukast Therapies Are Inversely Associated With A Common Variant Of The Corticotropin Releasing Hormone Receptor 1 (CRHR1) Gene. American Thoracic Society, Denver, CO, May 13-18, 2011.

19. Mougey, E.B., Chen, C., Tantisira, K.G., Blake, K.V., Peters, S., Robert A. Wise, R.A., Weiss, S.T., Lima,

J.J. A Common Variant Of The Muscarinic Cholinergic Receptor 2 (CHRM2) Gene Predicts Asthma Symptom Control During Fluticasone / Salmeterol Combination Therapy. American Thoracic Society, Denver, CO, May 13-18, 2011.

Edward B. Mougey


20. Mougey, E.B. Common Variant Of The Muscarinic Cholinergic Receptor 2 (CHRM2) Gene Predicts

Asthma Symptom Control During Fluticasone/Salmeterol Combination Therapy. Invited Platform Presentation, Ancillary Studies of the American Lung Association Asthma Clinical Research Centers. American Thoracic Society, San Francisco, CA May 18-23, 2012.

21. Mougey, E.B., Lang, J., Allayee, H., et al. Influence of ALOX5 hexanucleotide repeat polymorphism

on urinary leukotrienes in children with poorly controlled asthma. American Thoracic Society, San Francisco, CA May 18-23, 2012.

Documents

Edward B. Mougey CURRICULUM VITAE (2015_C).pdfCURRICULUM VITAE CONTACT INFORMATION Name: Edward B. Mougey Address: 1910 Hibernia Ct. Jacksonville, FL 32223 Telephone: (904) 292-1826